ethyl 4-(4-cyclohexyl-4-methoxypiperidin-1-yl)-benzoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-(4-cyclohexyl-4-methoxypiperidin-1-yl)-benzoate
• 英文别名: Ethyl 4-(4-cyclohexyl-4-methoxypiperidin-1-yl)benzoate
• 化学式: C₂₁H₃₁NO₃
• 分子量: 345.482
• InChiKey: AXKCIEQVJOZAOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-(4-cyclohexyl-4-methoxypiperidin-1-yl)-benzoate 在 1-羟基苯并三唑 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl (1r,4r)-4-(2-(4-(4-cyclohexyl-4-methoxypiperidin-1-yl)benzoyl)hydrazine-1-carbonyl)cyclohexane-1-carboxylate
  参考文献：
  名称：

  Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition

  摘要：

  The synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition and significantly improved MIC against Candida parapsilosis and echinocandin resistant-Candida is described. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.116
• 作为产物：
  描述：

  环己氯化镁 在 cerium(III) chloride 、 sodium hydride 、 potassium carbonate 、 苯甲醚 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 4-(4-cyclohexyl-4-methoxypiperidin-1-yl)-benzoate
  参考文献：
  名称：

  Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition

  摘要：

  The synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition and significantly improved MIC against Candida parapsilosis and echinocandin resistant-Candida is described. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.116

文献信息

• Cyclic hexapeptide derivatives
  申请人：——

  公开号：US20030083238A1

  公开（公告）日：2003-05-01

  This invention relates to new polypeptide compound represented by the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystic carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由普通式(I)所表示的新的多肽化合物，其中R1、R2、R3、R4、R5和R6如说明书中所定义，或其盐，具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，以及其制备方法、包含其的药物组合物，以及预防和/或治疗人类或动物的传染病（包括肺孢子虫感染，例如肺孢子虫肺炎）的方法。
• Development of a Practical and Scalable Synthesis of the Side Chain for ASP9726, a Successor of Micafungin
  作者：Shinya Yoshida、Atsushi Ohigashi、Yasuhiro Morinaga、Norio Hashimoto、Takumi Takahashi、Shigeru Ieda、Minoru Okada

  DOI：10.1021/op400211t

  日期：2013.10.18

  Here, we describe a practical and scalable synthesis of!, which is a useful side chain of ASP9726 (2), a successor of Micafungin. For large-scale synthesis of 1, reaction conditions were optimized to control impurities and increase yield. In particular, we utilized a high-yield thiadiazole ring formation to prepare thiadiazole 12, a step which was improved by optimization of reaction conditions and isolation method. Further, the number of steps was reduced from 10 to 9, and hazardous reactions were also avoided. Consequently, this process was scaled to produce 21.7 kg of 1 with overall yield improvement from 36.7% to 56.6%.
• CYCLIC HEXAPEPTIDE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1259535A1

  公开（公告）日：2002-11-27
• US6884774B2
  申请人：——

  公开号：US6884774B2

  公开（公告）日：2005-04-26
• [EN] CYCLIC HEXAPEPTIDE DERIVATIVES<br/>[FR] DERIVES CYCLIQUES D'HEXAPEPTIDES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001060846A1

  公开（公告）日：2001-08-23

  This invention relates to new polypeptide compound represented by the general formula (I) wherein R?1, R2, R3, R4, R5 and R6¿ are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystic carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.